Note: some babies had more than 1 side effect
How has this study helped patients and researchers?
This study showed that the 5-in-1 vaccine can doctors will be able to vaccinate babies with a
reduce the number of injections needed to single vaccine instead of separate vaccines.
protect Russian babies against 5 childhood
This summary only shows results from 1 study.
diseases. These results can be submitted to the
Other studies may find different results.
Russian health authority for approval of the
vaccine. If this vaccine is approved in Russia,
Are there plans for further studies?
At the time of preparation of this summary, no further studies were planned with the 5-in-1 vaccine in
Russian babies.
Where can I find more information about this study?
The detailed title for this research study is:
A phase III, open-label study to assess the immunogenicity and reactogenicity of GSK Biologicalsâ€™ DTPa-
IPV/Hib vaccine administered as a three-dose primary vaccination course at 3, 4.5 and 6 months of age
and a booster dose at 18 months of age in healthy infants in Russia.
Clinical studies have unique study numbers. Below are the unique study numbers associated with this
study.
Organization Website Study Number
European Medicines Agency www.clinicaltrialsregister.eu 2013-005577-43
United States National Institutes www.clinicaltrials.gov NCT02858440
of Health (NIH)